Japan: A recent study has revealed that replacing angiotensin II receptor blockers (ARBs) with sacubitril/valsartan can ...

Novartis markets and sells a combination therapy of valsartan and sacubitril under the brand name Entresto® for the treatment of various forms ...

There are hints that the 10-year benefit seen in STICHES, the earlier trial, might be the result of inferior medical therapy.

In patients with acute heart failure, it is unclear how body mass index affects clinical outcomes following acute myocardial infarction.

Mumbai: Global pharma major Lupin Limited has announced that it has launched Rivaroxaban Tablets USP, 2.5 mg, following the ...

Obesity is a raging conversation globally now, and manufacturing of generics will pick up after the patent expires.' ...

AT-II-receptor antagonists include losartan, valsartan, irbesartan, candesartan, eprosartan, telmisartan, and tasosartan. Several clinical trials have demonstrated that AT-II-receptor antagonists ...

Bayer has claimed EU approval for Kerendia, its new drug for chronic kidney disease (CKD) in people with type 2 diabetes, as the company tries to build a role of the drug alongside rival therapies ...

We evaluated the novel use of valsartan to attenuate the occurrence of and progression of pulmonary vein stenosis following total anomalous pulmonary venous connection surgery. Subclinical pulmonary ...

A substudy of the VANISH randomized clinical trial, published March 5 in JAMA Cardiology, identified potential benefit of valsartan for cardiac remodeling and indexed intracellular volume in patients ...